Frank Vinluan / medcitynews - Leucovorin is now approved for cerebral folate deficiency months after FDA Commissioner Marty Makary claimed the decades-old generic drug had promise for treating autism. The FDA’s review was based on published literature and real-world evidence.The post …
AI Summary: The FDA has granted traditional approval to leucovorin for cerebral folate deficiency, formalizing a decades‑old generic’s role in a rare metabolic disorder. The decision comes amid earlier agency notes that evidence for autism benefit was weak and debate over expanding use without fresh trial data — cue the policy hot takes.
FDA commissioner Marty Makary resigns amid mounting scrutiny / 19 days
FDA Abortion Pill Decisions Rooted in Science / 4 months
FDA loosens data restrictions to accelerate drug reviews / 5 months
FDA Appoints Richard Pazdur to Lead Drug Division Amid Regulatory Shifts / 6 months
FDA links eight deaths to Amgen’s Tavneos; scrutiny intensifies / 1 month
FDA launches individualized therapy framework for ultra-rare diseases / 3 months
FDA makes one pivotal trial the default for drug approvals / 3 months
StackHealth RSS

StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.